نتائج البحث

Nivolumab plus chemotherapy or ipilimumab versus chemotherapy in patients with advanced esophageal squamous cell carcinoma (CheckMate 648):29-month follow-up from a randomized, open-label, phase III trial

• Authors : Kato, Ken; Doki, Yuichiro; Chau, Ian

Subjects: cancer management; check point control; chemotherapy

• Source: Kato , K , Doki , Y , Chau , I , Xu , J , Wyrwicz , L , Motoyama , S , Ogata , T , Kawakami , H , Hsu , C H , Adenis , A , El Hajbi , F , Di Bartolomeo , M , Braghiroli , M I , Holtved , E , Makino ,

تفاصيل العنوان

Comparison of efficacy in patients with metastatic melanoma treated with ipilimumab and nivolumab who did or did not discontinue treatment due to immune-related adverse events:A real-world data study

• Authors : Fink, Morten; Vittrup, Anders Schwartz; Bastholt, Lars

Subjects: DAMMED; Immune-related adverse events; Immunotherapy

• Source: Fink , M , Vittrup , A S , Bastholt , L , Svane , I M , Donia , M , Luczak , A A , Ruhlmann , C H , Guldbrandt , L M , Koehler , U H , Winther , M L , Ellebaek , E , Haslund , C A & Schmidt , H 2021 ,

تفاصيل العنوان

Final Analysis of the Ipilimumab Versus Placebo Following Radiotherapy Phase III Trial in Postdocetaxel Metastatic Castration-resistant Prostate Cancer Identifies an Excess of Long-term Survivors

• Authors : Fizazi, Karim; Drake, Charles G.; Beer, Tomasz M.

Subjects: Immunotherapy; Ipilimumab; Prostate cancer

• Source: Fizazi , K , Drake , C G , Beer , T M , Kwon , E D , Scher , H I , Gerritsen , W R , Bossi , A , den Eertwegh , A J M V , Krainer , M , Houede , N , Santos , R , Mahammedi , H , Ng , S , Danielli , R

تفاصيل العنوان

Development of anti-drug antibodies is associated with shortened survival in patients with metastatic melanoma treated with ipilimumab

• Authors : Kverneland, Anders H.; Enevold, Christian; Donia, Marco

Subjects: anti-drug antibodies; cancer; checkpoint inhibitors

• Source: Kverneland , A H , Enevold , C , Donia , M , Bastholt , L , Svane , I M & Nielsen , C H 2018 , ' Development of anti-drug antibodies is associated with shortened survival in patients with metastatic

تفاصيل العنوان

Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy

• Authors : Eggermont, Alexander M M; Chiarion-Sileni, Vanna; Grob, Jean-Jacques

Subjects: Adjuvants; Immunologic; Adolescent

• Source: Eggermont , A M M , Chiarion-Sileni , V , Grob , J-J , Dummer , R , Wolchok , J D , Schmidt , H , Hamid , O , Robert , C , Ascierto , P A , Richards , J M , Lebbé , C , Ferraresi , V , Smylie , M ,

تفاصيل العنوان

Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma

• Authors : Ascierto, Paolo Antonio; Del Vecchio, Michelle; Mackiewicz, Andrzej

Subjects: immunology; oncology; randomized trials

• Source: Ascierto , P A , Del Vecchio , M , Mackiewicz , A , Robert , C , Chiarion-Sileni , V , Arance , A , Lebbé , C , Svane , I M , Mcneil , C , Rutkowski , P , Loquai , C , Mortier , L , Hamid , O ,

تفاصيل العنوان

Five-year survival with combined nivolumab and ipilimumab in advanced melanoma

• Authors : Larkin, J.; Chiarion-Sileni, V.; Gonzalez, R.

• Source: Larkin , J , Chiarion-Sileni , V , Gonzalez , R , Grob , J J , Rutkowski , P , Lao , C D , Cowey , C L , Schadendorf , D , Wagstaff , J , Dummer , R , Ferrucci , P F , Smylie , M , Hogg , D , Hill , A

تفاصيل العنوان

PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1 monotherapy in metastatic melanoma

• Authors : Ellebaek, Eva; Khan, Shawez; Bastholt, Lars

Subjects: Anti-CTLA-4; Anti-PD-1; Immunotherapy

• Source: Ellebaek , E , Khan , S , Bastholt , L , Schmidt , H , Haslund , C A , Donia , M & Svane , I M 2024 , ' PD-L1 is a biomarker of real-world clinical outcomes for anti-CTLA-4 plus anti-PD-1 or anti-PD-1

تفاصيل العنوان

Nivolumab Combination Therapy in Advanced Esophageal Squamous-Cell Carcinoma

• Authors : Doki, Yuichiro; Ajani, Jaffer A.; Kato, Ken

Subjects: Adult; Aged; 80 and over

• Source: Doki , Y , Ajani , J A , Kato , K , Xu , J , Wyrwicz , L , Motoyama , S , Ogata , T , Kawakami , H , Hsu , C H , Adenis , A , El Hajbi , F , Di Bartolomeo , M , Braghiroli , M I , Holtved , E ,

تفاصيل العنوان

Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune checkpoint inhibitor for metastatic melanoma

• Authors : Bastholt, Lars; Schmidt, Henrik; Bjerregaard, Jon Kroll

Subjects: Age; Anti-CTLA4; Anti-PD1

• Source: Bastholt , L , Schmidt , H , Bjerregaard , J K , Herrstedt , J & Svane , I M 2019 , ' Age favoured overall survival in a large population-based Danish patient cohort treated with anti-PD1 immune

تفاصيل العنوان